Objective: Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA).
Methods: Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included.
Results: In total, 150 patients initiated monotherapy (apremilast: n = 34; MTX: n = 15; bDMARD: n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators.
Conclusion: Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3899/jrheum.191209 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of apremilast on hand and whole-body MRI assessments of inflammation in patients with psoriatic arthritis (MOSAIC): a phase 4, multicentre, single-arm, open-label study.
Lancet Rheumatol
October 2024
Swedish Medical Center-Providence St Joseph Health, School of Medicine, University of Washington, Seattle, WA, USA.
Background: The Psoriatic Arthritis Magnetic Resonance Imaging Scoring System (PsAMRIS) and MRI Whole-Body Scoring System for Inflammation in Peripheral Joints and Entheses in Inflammatory Arthritis (MRI-WIPE) have not been used together to assess treatment of psoriatic arthritis in a clinical trial. We aimed to assess the effect of apremilast treatment on inflammation, with outcomes measured by PsAMRIS and MRI-WIPE.
Methods: MOSAIC was a phase 4, multicentre, single-arm, open-label study conducted at 29 sites across ten countries (Belgium, Canada, Denmark, Germany, Italy, Russia, Spain, Switzerland, the UK, and the USA).
Pharmacotherapeutic management of psoriatic disease: addressing psoriatic arthritis and cutaneous manifestations.
Expert Opin Pharmacother
November 2024
Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Article Synopsis
- Psoriasis and psoriatic arthritis (PsA) are related autoimmune diseases that often occur together, with PsA possibly developing within 10 years after psoriasis begins.
- The review discusses current treatments for both conditions and provides guidelines for managing psoriasis and PsA effectively.
- For mild cases, topical treatments and NSAIDs are recommended, while severe cases may require systemic treatments or biologics; a personalized approach is crucial for optimizing patient care and outcomes.
Patients' Preferences Regarding Modes of Systemic Psoriasis Treatment - A Qualitative Study.
J Psoriasis Psoriatic Arthritis
October 2024
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Article Synopsis
- Treatment options for psoriasis have expanded, allowing patients to选择 between biologics delivered via injections and oral systemic medications based on personal preference.
- A study involving 22 psoriasis patients explored factors influencing their treatment choices, revealing five key themes regarding quality of life, side effect fears, needle aversion, convenience, and physician recommendations.
- The conclusion suggests that tailoring treatment plans to align with patient preferences while promoting shared decision-making can enhance medication adherence and overall health outcomes.
2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore.
Ann Acad Med Singap
September 2024
Dr SN Wong Skin, Hair, Nails & Laser Specialist Clinic, Singapore.
Article Synopsis
- Psoriasis is a chronic inflammatory skin disease that requires varied management approaches, which the study aimed to standardize through new guidelines tailored for dermatology practice in Singapore.
- A specialized workgroup conducted a comprehensive literature review on psoriasis treatments from 2013 to 2023, refining clinical questions to create practical guidelines covering assessment and management strategies for different severity levels of psoriasis.
- The resulting guidelines suggest various therapies, including both systemic and topical treatments, while addressing specific concerns for special populations and providing recommendations for managing related conditions like psoriatic arthritis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!